PP_1170x120_10-25-21

Tobi Inhalation Solution

Aurobindo gets FDA approval for tobramycin inhalation stolution

Aurobindo gets FDA approval for tobramycin inhalation stolution

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tobramycin inhalation solution, 300 mg/5 mL. Aurobindo Pharma’s Tobramycin Inhalation Solution, 300 mg/5 mL are an AB-rated generic equivalent to the reference listed drug (RLD), Tobi Inhalation Solution, 300 mg/5 mL marketed

Adheris Health